PFA Pension Forsikringsaktieselskab Buys Shares of 188,393 ResMed Inc. $RMD

PFA Pension Forsikringsaktieselskab bought a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 188,393 shares of the medical equipment provider's stock, valued at approximately $45,794,000. PFA Pension Forsikringsaktieselskab owned 0.13% of ResMed as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Bogart Wealth LLC lifted its holdings in ResMed by 2.3% in the fourth quarter. Bogart Wealth LLC now owns 18,018 shares of the medical equipment provider's stock valued at $4,340,000 after acquiring an additional 406 shares during the period. Keybank National Association OH lifted its holdings in ResMed by 8.0% in the fourth quarter. Keybank National Association OH now owns 139,177 shares of the medical equipment provider's stock valued at $33,524,000 after acquiring an additional 10,346 shares during the period. Vest Financial LLC lifted its holdings in ResMed by 123.8% in the fourth quarter. Vest Financial LLC now owns 98,002 shares of the medical equipment provider's stock valued at $23,606,000 after acquiring an additional 54,214 shares during the period. Certuity LLC lifted its holdings in ResMed by 561.7% in the fourth quarter. Certuity LLC now owns 6,736 shares of the medical equipment provider's stock valued at $1,623,000 after acquiring an additional 5,718 shares during the period. Finally, Torren Management LLC acquired a new stake in ResMed in the fourth quarter valued at $62,000. Institutional investors and hedge funds own 54.98% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on RMD shares. Evercore set a $255.00 target price on ResMed and gave the company an "outperform" rating in a report on Monday, April 13th. Robert W. Baird set a $225.00 price target on ResMed in a research report on Friday. Wells Fargo & Company dropped their price target on ResMed from $270.00 to $227.00 and set an "equal weight" rating for the company in a research report on Friday. Piper Sandler raised their price target on ResMed from $270.00 to $275.00 and gave the company a "neutral" rating in a research report on Friday, January 30th. Finally, Royal Bank Of Canada raised their price target on ResMed from $314.00 to $321.00 and gave the company an "outperform" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $286.18.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

Insider Transactions at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $225.50, for a total transaction of $1,125,470.50. Following the completion of the sale, the chief executive officer owned 466,223 shares in the company, valued at approximately $105,133,286.50. This trade represents a 1.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 21,023 shares of company stock valued at $5,230,857. 0.65% of the stock is currently owned by company insiders.

ResMed Trading Down 4.0%

Shares of RMD stock opened at $205.17 on Friday. ResMed Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $293.81. The stock has a market cap of $29.89 billion, a P/E ratio of 19.79, a P/E/G ratio of 1.35 and a beta of 0.85. The business has a fifty day simple moving average of $233.35 and a 200-day simple moving average of $246.50. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, beating analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The business had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $1.42 billion. During the same quarter last year, the business posted $2.37 earnings per share. The business's revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts forecast that ResMed Inc. will post 11.07 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed's dividend payout ratio (DPR) is currently 23.74%.

ResMed Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.